SC
CATX icon

Sykon Capital’s Perspective Therapeutics CATX Stock Holding History

Sykon Capital’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Hold
37,932
– – 0.04% 110
2026
Q1 		$158K Hold
37,932
– – 0.05% 86
2025
Q4 		$104K Hold
37,932
– – 0.03% 117
2025
Q3 		$130K Hold
37,932
– – 0.04% 100
2025
Q2 		$130K Hold
37,932
– – 0.05% 83
2025
Q1 		$80.8K Hold
37,932
– – 0.03% 63
2024
Q4 		$121K Hold
37,932
– – 0.04% 62
2024
Q3 		$506K Hold
37,932
– – 0.18% 65
2024
Q2 		$378K Buy
37,932
+34,310
+947% +$496K 0.14% 60
2024
Q1 		$43.1K Buy
+3,622
New +$30.9K 0.02% 92

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Sykon Capital's CATX Position: Q2 2026 in Review

Sykon Capital held its Perspective Therapeutics (CATX) position steady in Q2 2026 at 37,932 shares worth $129K. The position accounts for 0.04% of the portfolio, ranked #110.

Sykon Capital first reported a position in CATX in Q1 2024 and has held it in 10 quarters since. The position peaked at $506K in Q3 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Sykon Capital held 37,932 shares of Perspective Therapeutics worth $129K as of Q2 2026.
  • Sykon Capital left its Perspective Therapeutics share count unchanged in Q2 2026.
  • Perspective Therapeutics made up 0.04% of Sykon Capital's portfolio in Q2 2026, its #110 holding.
  • Sykon Capital first reported a position in Perspective Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Sykon Capital's Perspective Therapeutics position peaked at $506K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Sykon Capital's 13F filing for Q2 2026, filed 12 Aug 2026.